MRNA monthly performance report
Explore MRNA's monthly returns, drawdown, and seasonality trends — updated every month.
MRNA monthly report
—
Key takeaways
- Moderna (MRNA) closed November 2026 at $223.37, up 0.74% for the month and +794.91% over the trailing 12 months.
- Year-to-date, MRNA is +657.44%, outperforming the S&P 500 which has returned +10.62% YTD.
- The stock is trading +131.69% versus its 200-day moving average ($96.41), a bullish technical signal.
- Over the past three years, MRNA has outperformed the S&P 500 by +146.77%, with a relative strength index reading of 185.6.
- Win rate over the trailing 39 months stands at 53.8% — 21 positive months versus 18 negative months.
Moderna ended November 2026 at $223.37, posting a monthly return of +0.74%. The S&P 500 returned −0.18% over the same window, leaving relative performance at +0.92%.
The current quarter stands at +15.99% (Q4 2026 (QTD)), while medium-term trend remains constructive: price is +131.69% versus the 200-day moving average ($96.41).
Year-to-date, MRNA is +657.44% against SPY +10.62%, a gap of +646.82%. The stock is currently −20.45% below its 52-week high, with maximum 3-year drawdown at −86.58%.
| Period | MRNA | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | −3.45% | −0.36% | −3.09% |
| 1 Week | −12.12% | +2.59% | −14.72% |
| 1 Month | +0.74% | −0.18% | +0.92% |
| 3 Months | +246.52% | −2.37% | +248.89% |
| 6 Months | +346.47% | +0.83% | +345.64% |
| YTD | +657.44% | +10.62% | +646.82% |
| 12 Months | +794.91% | +12.25% | +782.66% |
| 3 Years | +218.15% | +71.37% | +146.77% |
| Rank | Month | Return |
|---|---|---|
| #1 | Aug 2026 | +156.00% |
| #2 | Jan 2026 | +49.44% |
| #3 | Jun 2026 | +48.40% |
| #4 | Sep 2026 | +37.22% |
| #5 | May 2024 | +29.23% |
| Rank | Month | Return |
|---|---|---|
| #1 | Aug 2024 | −35.08% |
| #2 | Oct 2023 | −26.46% |
| #3 | Jul 2026 | −21.72% |
| #4 | Feb 2025 | −21.46% |
| #5 | Nov 2024 | −20.79% |
| Quarter | Return |
|---|---|
| Q3 2025 | −6.38% |
| Q4 2025 | +14.17% |
| Q1 2026 | +72.26% |
| Q2 2026 | +37.85% |
| Q3 2026 | +174.98% |
| Q4 2026 (QTD) | +15.99% |
| Year | Return |
|---|---|
| 2023 | −44.63% |
| 2024 | −58.19% |
| 2025 | −29.08% |
| 2026 | +657.44% |
| Metric | Value |
|---|---|
| 52-Week High | $280.80 (2026-11-09) |
| 52-Week Low | $22.28 (2025-11-21) |
| Current Price | $223.37 |
| 200-Day Moving Average | $96.41 |
| Price vs 200DMA | +131.69% |
| 3-Year Maximum Drawdown | −86.58% (2025-11-20) |
| Current Drawdown from 52W High | −20.45% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 185.6 |
| 3-Year Excess Return vs S&P 500 | +146.77% |
| RS Peak | 224.1 (Nov 2026) |
| RS Trough | 21.5 (Nov 2025) |
| Status | Outperforming Benchmark |
Frequently asked questions
What was MRNA's return for this report period?
MRNA returned +0.74% in the latest monthly window ending 2026-11-13.
Has MRNA outperformed SPY year to date?
YTD MRNA: +657.44% vs SPY: +10.62%.
What is MRNA's 12-month return?
+794.91% over the trailing 12 months.
Is MRNA above or below its 200-day moving average?
Price is +131.69% versus 200DMA ($96.41).
What is the maximum drawdown in the 3-year window?
−86.58% on 2025-11-20.